nach oben

Erschienen in:

2023 | OriginalPaper | Buchkapitel

5. Antidepressiva

verfasst von : Priv.-Doz. Dr. med. Regina Taurines, Prof. Dr. rer. nat. Manfred Gerlach

Erschienen in: Neuro-/Psychopharmaka im Kindes- und Jugendalter

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

„Antidepressiva“ umfassen eine heterogene Klasse von Wirkstoffen, die ursprünglich vorwiegend bei Patienten mit depressiven Symptomen eingesetzt wurden, heute aber eine weit über die depressive Störung hinausgehende therapeutische Anwendung finden. In diesem Kapitel wird zunächst auf die Terminologie und Einteilung von Antidepressiva eingegangen. Dann wird der aktuelle Wissensstand zu deren Wirkmechanismen besprochen, und es werden schwerpunktmäßig diejenigen pharmakologischen Aspekte von in der Kinder- und Jugendpsychiatrie verwendeten Antidepressiva dargestellt, die für die klinisch tätige Ärzteschaft relevant sind. Dabei wird auf die Anwendungsgebiete und Studienlage zur klinischen Wirksamkeit eingegangen. Es werden Dosierungsempfehlungen gegeben und mögliche unerwünschte Arzneimittel- und Pharmakawechselwirkungen behandelt. Das Kapitel schließt mit Empfehlungen zur Behandlungsdauer sowie zu notwendigen Kontrolluntersuchungen.

Alderman J, Wolkow R, Fogel IM (2006) Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. J Child Adol Psychop 16:117–129CrossRef

Ambrosini PJ (2000) A review of pharmacotherapy of major depression in children and adolescents. Psychiat Serv 51:627–633CrossRef

Amitai M, Taler M, Lebov M et al. (2020) An increase in IL-6 levels at 6-month follow-up visit is associated with SSRI-emergent suicidality in high-risk children and adolescents treated with fluoxetine. Eur Neuropsychopharmacol 40:61–69PubMedCrossRef

Anderson JW, Greenway FL, Fujioka K et al. (2002) Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 10:633–641PubMedCrossRef

Arabgol F, Panaghi L, Hebrani P (2009) Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder. Eur Child Adolesc Psy 18:53–59CrossRef

Arango C, Buitelaar JK, Fegert JM et al. (2022) Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries. Lancet Psychiatry 9:113–124PubMedCrossRef

Attia E, Haiman C, Walsh BT, Flater SR (1998) Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 155:548–551PubMedCrossRef

Atkinson SD, Prakash A, Zhang Q et al. (2014) A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 24:180–189PubMedCrossRef

Avci A, Diler RS, Kibar M, Sezgin F (1999) Comparison of moclobemide and placebo in young adolescents with major depressive disorder. Ann Med Sci 8:31–40

AWMF (2021) Leitlinie der Deutschen Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (DGKJP): Langversion der interdisziplinären evidenz- und konsensbasierten S3-Leitlinie für Diagnostik und Therapie von Zwangsstörungen im Kindes- und Jugendalter. AWMF-Register Nr. 028-007. https://www.awmf.org/leitlinien/detail/ll/028-007.html. Zugegriffen: 25. Okt. 2021

Bacaltchuk J, Hay P, Mari JJ (2000) Antidepressants versus placebo for the treatment of bulimia nervosa: a systematic review. Aust N Z J Psychiatry 34:310–317PubMedCrossRef

Ballard ED, Ionescu DF, Vande Voort JE et al. (2014) Improvement in suicidal ideation after ketamine infusion: relationship to reduction in depression and anxiety. J Psychiatr Res 58:161–166PubMedCrossRef

Ballester P, Martínez MJ, Inda MD et al. (2019) Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability. J Psychopharmacol 33:1395–1406PubMedCrossRef

Bandelow B, Bleich S, Kropp S (Hrsg) (2011) Handbuch Psychopharmaka, 3. Aufl. Hogrefe, Göttingen

Barrickman LL, Perry PJ, Allen AJ et al. (1995) Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Ps 34:649–657CrossRef

Bech (2001) Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 4:337–345PubMedCrossRef

Bello NT, Yeomans BL (2019) Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opin Drug Saf 17:17–23CrossRef

Bezchlibnyk-Butler KZ, Virani AS (Hrsg) (2007) Clinical handbook of psychotropic drugs for children and adolescents, 2. Aufl. Hogrefe & Huber, Seattle

Biedermann J, Herzog DB, Rivinus TM (1985) Amitriptyline in the treatment of anorexia nervosa: a double-blind placebo-controlled study. J Clin Psychopharmacol 5:10–16CrossRef

Birmaher B, Waterman GS, Ryan N, Cully M, Balach L, Ingram J, Brodsky M (1994) Fluoxetine for childhood anxiety disorders. Am Acad Child Adolesc Psychiatry 33:993–999

Birmaher B, Axelson DA, Monk K et al. (2003) Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Psy 42:415–423CrossRef

Black B, Uhde TW (1994) Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study. J Am Acad Child Psychiatry 33:1000–1006CrossRef

Blazquez A, Mas S, Plana MT, Lafuente A, Lázaro L (2012) Fluoxetine pharmacogenetics in child and adult populations. Eur Child Adolesc Psy 21:599–610CrossRef

Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C (2010) Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry 15:850–855PubMedCrossRef

Boaden K, Tomlinson A, Cortese S, Cipriani A (2020) Antidepressants in children and adolescents: meta-review of efficacy, Tolerability and Suicidality in acute Treatment. Front Psychiatry 11:717PubMedPubMedCentralCrossRef

Braconnier A, Coent RL, Cohen D (2003) Paroxetine versus clomopramine in adolescents with severe major depression: a double-blind randomized, multicenter trial. J Child Am Child Psy 42:22–29CrossRef

Brent D, Emslie G, Clarke G et al. (2008) Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA J Am Ned Assoc 299:901–913CrossRef

Bridge JA, Jyengar S, Salary CB et al. (2007) Clinical response and risk for suicidal ideation and suicide attempts in pediatric antidepressant treatment. JAMA J Am Ned Assoc 297:1683–1696CrossRef

Briggs GG, Ambrose PJ, Ilett KF et al. (2009) Use of duloxetine in pregnancy and lactation. Ann Pharmacother 43:1898–1902PubMedCrossRef

Cahill K, Stevens S, Perera R, Lancaster T (2013) Pharmacological interventions for smoking cessation: an overview and network meta-analysis (Review). Cochrane Database Sys Rev 5:CD9329

Carlson JS, Kratochwill TR, Johnston HF (1999) Sertraline treatment of 5 children diagnosed with selective mutism: a single-case research trial. J Child Adol Psychoph 9:293–306CrossRef

Casarotto PC, Girych M, Fred SM et al. (2021) Antidepressant drugs acty by directly binding to TRKB neurotrophin receptors. Cell 184:1299–1313PubMedPubMedCentralCrossRef

Chermà MDD, Ahlner J, Bengtsson F, Gustafsson PA (2011) Antidepressant drugs in children and adolescents: analytical and demographic data in a naturalistic, clinical study. J Clin Psychopharmacol 31:98–102PubMedCrossRef

Cipriani A, Kosters M, Furukawa TA et al. (2012) Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006533.pub2CrossRefPubMed

Cipriani A, Zhou X, Del Giovane C, Hetrik SE, Qin B, Whittington C et al (2016) Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolesecents: a network meta-analysis. Lancet 388:881–890

Cohen JA, Mannarino AP, Perel JM, Staron V (2007) A pilot randomized controlled trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms. J Am Acad Child Psy 46:811–819CrossRef

Cohen-Yavin I, Yoran-Hegesh R, Strous RD et al. (2009) Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial. Clin Neuropharmacol 32:179–182PubMedCrossRef

Correll CU, Cortese S, Croatto G et al. (2021) Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interven-tions in children and adolescents with mental disorders: an umbrella review. World Psychiatry 20:244–275PubMedPubMedCentralCrossRef

Cortese S, Adamo N, Del Giovane C et al. (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5:727–738PubMedPubMedCentralCrossRef

Cryan JF, Bruijnzeel AW, Skjei KL, Markou A (2003) Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168:347–358PubMedCrossRef

Daviss WB, Bentivoglio P, Racusin R et al. (2001) Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Psy 40:307–314CrossRef

De Jonghe F, Ravelli DP, Tuynman-Qua H (1991) A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 24:62–67PubMedCrossRef

Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, DGKJP (2013) Behandlung von depressiven Störungen bei Kindern und Jugendlichen, Evidenz- und konsensusbasierte Leitlinie (S3), AWMF-Registernummer 028–043. https://register.awmf.org/de/leitlinien/detail/028-043. Zugegriffen: 28. Sept. 2015

DeVeaugh-Geiss J, Moroz G et al. (1992) Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder – a multicenter trial. J Am Acad Child Psy 31:45–49CrossRef

Dobson ET, Bloch MH, Strawn JR (2019) Efficacy and tolerability of pharma-cotherapy for pediatric anxiety disorders: a network meta-analysis. J Clin Psychiatry 80:17r12064PubMedCrossRef

Donnelly CL, Wagner KD, Rynn M et al. (2006) Sertraline in children and adolescents with major depressive disorder. J Am Acad Child Psy 45:1162–1170CrossRef

Dubrall D, Fekete S, Leitzen S et al. (2023) Selective serotonin reuptake inhibitors and suicidality in children and young adults: analyses of pharmacovigilance databases. BMC Pharmacol Toxicol 24:22. https://doi.org/10.1186/s40360-023-00664-zCrossRefPubMedPubMedCentral

Dugas M, Mouren MC, Halfon O, Moron P (1985) Treatment of childhood and adolescent depression with mianserin. Acta Psychiat Scand 320:48–53CrossRef

Dwyer JB, Landeros-Weisenberger A, Johnson JA et al. (2021) Efficacy of intravenous ketamine in adolescent treatment-resistant depression: A randomized midazolam-controlled trial. Am J Psychiatry 178:352–362PubMedCrossRef

Edwarts JG, Anderson I (1999) Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57:507–533CrossRef

Emslie GJ, Rush AJ, Weinberg WA et al. (1997) A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Ach Gen Psychiat 54:1031–1037CrossRef

Emslie GJ, Heiligenstein JH, Wagner KD et al. (2002) Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Psy 41:1205–1215CrossRef

Emslie GJ, Wagner KD, Kutcher S et al. (2006) Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Psy 45:709–719CrossRef

Emslie GJ, Yeung PP, Kunz NR (2007) Long-term, open-label venlafaxine extended-release treatment in children and adolescents with major depressive disorder. CNS Spectr 12:223–233PubMedCrossRef

Emslie GJ, Kennard BD, Mayes TL et al. (2008) Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiat 165:459–467PubMedCrossRef

Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S (2009) Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 48:721–729PubMedCrossRef

Emslie GJ, Prakash A, Zhang Q et al. (2014) A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 24:170–179PubMedPubMedCentralCrossRef

Entsuah AR, Huang H, Thase ME (2001) Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiat 62:869–877CrossRef

Fava GA, Bernardi M, Tomba E, Rafanelli C (2007) Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychop 10:835–838CrossRef

Ferguson CP, La Via MC, Crossan PJ, Kaye WH (1999) Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int J Eat Disord 25:11–17PubMedCrossRef

Figueroa R (2010) Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J Dev Behav Pediatr 31:641–618PubMedCrossRef

Findling RL, McNamara NK, O’Riordan MA et al. (2003) An open-label pilot study of St. John’s wort in juvenile depression. J Am Acad Child Psy 42:908–914CrossRef

Flament MF, Rapoport JL, Berg CJ et al. (1985) Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiat 42:977–983PubMedCrossRef

Fluoxetine Bulimia Nervosa Collaborative Study Group (1992) Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 49:139–147CrossRef

Geller DA, Hoog SL, Heiligenstein JH et al. (2001) Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Psy 40:773–779CrossRef

Geller DA, Biedermann J, Stewart SE et al. (2003) A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiat 160:1919–1928PubMedCrossRef

Gentile S (2011) Efficacy of antidepressant medications in children and adolescents with obsessive-compulsive disorder: a systematic appraisal. J Clin Psychopharm 31:625–632CrossRef

Gerlach M (2021) Pharmakologische und rechtliche Grundkenntnisse der Psychopharmakotherapie. Psych Up2date 15:71–84CrossRef

Gerlach M, Warnke A (2021) Pocket Guide Neuro-/Psychopharmaka im Kindes- und Jugendalter, 2. Aufl. Springer, BerlinCrossRef

Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2006) The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiat 163:1898–1904PubMedCrossRef

Gibbons RD, Brown CH, Hur K et al. (2007) Early evidence on the effects of regulator´s warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 164:1356–1363PubMedCrossRef

Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ (2012) Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiat 69:580–587PubMedCrossRef

Glazener CM, Evans JH, Peto RE (2003) Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002117CrossRefPubMed

Glod CA, Lynch A, Flynn E, Berkowitz C, Baldessarini RJ (2003) Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs 16:123–130PubMedCrossRef

Golubchik P, Sever J, Weizman A (2013) Reboxetine treatment for autistic spectrum disorder of pediatric patients with depressive and inattentive/hyperactive symptoms: an open-label trial. Clin Neuropharmacol 36:37–41PubMedCrossRef

Goodyer IM, Dubicka B, Wilkinson P et al. (2008) A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technol Assess 12:1CrossRef

Gosmann NP, Costa MA, Jaeger MB et al. (2021) Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: a 3-level network meta-analysis. meta-analysis. PLoS Med 18:e1003664PubMedPubMedCentralCrossRef

Haapasalo-Pesu KM, Vuola T, Lahelma L, Marttunen M (2004) Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. J Child Adol Psychop 14:175–184CrossRef

Haddad P (1998) The SSRI discontinuation syndrome. J Psychopharmacol 12:305–313PubMedCrossRef

Halmi KA, Eckert ED, LaDu TJ, Cohen J (1986) Anorexia nervosa: treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry 43:177–181PubMedCrossRef

Hay PJ, Claudino AM (2012) Clinical psychopharmacology of eating disorders: a research update. Int J Neuropsychopharmacol 15:209–222PubMedCrossRef

Hazell P (2009) Depression in children and adolescents. Clin Evid 1:1008

Hazell P, Mirzaie M (2013) Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 6:CD2317

Hegerl U, Hensch T (2014) The vigilance regulation model of affective disorders and ADHD. Neurosci Biobehav Rev 44:45–57PubMedCrossRef

Henry JA, Alexander CA, Sener EK (1995) Relative mortality from overdose of antidepressants. Br Med J 310:221–224CrossRef

Hepgul N, Cattaneo A, Zunszain PA, Pariante CM (2013) Depression pathogenesis and treatment: what can we learn from blood mRNA expression? BMC Med 11:Article number 28CrossRef

Hetrick S, McKenzie JE, Bailey AP et al. (2021) New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013674.pub2CrossRefPubMedPubMedCentral

Hewett K, Chrzanowski W, Schmitz M et al. (2009) Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 23:531–538PubMedCrossRef

Hiemke C (2009) Pharmakologie von Agomelatonin. Psychopharmakotherapie 16(Suppl 19):2–5

Hiemke C, Härtter S (2000) Pharmakokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85:11–28PubMedCrossRef

Hiemke C, Bergemann N, Clement HW et al. (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology – Update 2017. Pharmacopsychiatry 51:9–62PubMedCrossRef

Hirschtritt ME, Pagano ME, Christian KM et al. (2012) Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders. J Subst Abuse Treat 42:366–372PubMedCrossRef

Holtkamp K, Konrad K, Kaiser N et al. (2005) A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy. J Psychiatr Res 39:303–310PubMedCrossRef

Holtmann M, Bölte S, Poustka F (2006) Suicidality in depressive children and adolescents during treatment with selective serotonin reuptake inhibitors. Review and meta-analysis of the available randomised, placebo controlled trials. Nervenarzt 77:1332–1337PubMedCrossRef

Hori H, Yoshimura R, Ueda N et al. (2003) Grapefruit juice-fluvoxamine interaction – is it risky or not? J Clin Psychopharmacol 23:422–424PubMedCrossRef

Horst WD, Preskorn SH (1998) Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 51:237–254PubMedCrossRef

Howes OD, Rogdaki M, Findon JL et al. (2018) Autism Spectrum Disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol 32:3–29PubMedCrossRef

Hudziak JJ, Rettew DC (2004) Bupropion. In: Schatzberg AF, Nemeroff CB (Hrsg) Textbook of psychopharmacology, 3. Aufl. American Psychiatric Publishing, Washington, S 327–339

Ignaszewski MJ, Waslick B (2018) Update on randomized placebo-controlled trials in the past decade for treatment of major depressive disorder in child and adolescent patients: A systematic review. J Child Adolesc Psychopharmacol 28:668–675PubMedCrossRef

Jackson CW, Cates M, Lorenz R (2010) Pharmacotherapy of eating disorders. Nutr Clin Prac 25:143–159CrossRef

Jafarinia M, Mohammadi MR, Modabbernia A et al. (2012) Bupropion versus methyphenidate in the treatment of children with attention-deficit/hyperactivity disorders: Randomized double-blind study. Hum Psychopharm Clin 27:411–418CrossRef

Jain AK, Kaplan RA, Gadde KM et al. (2002) Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obes Res 10:1049–1056PubMedCrossRef

Kaakeh Y, Stumpf JL (2008) Treatment of selective mutism: focus on selective serotonin reuptake inhibitors. Pharmacotherapy 28:214–224PubMedCrossRef

Kasper S, Caraci F, Forti B, Drago F, Aguglia E (2010) Efficacy and tolerability of Hypericum extract for the treatment of mild to moderated depression. Eur Neuropsychopharm 20:747–765CrossRef

Keller MB, Ryan ND, Strober M et al. (2001) Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Child Am Child Psy 40:762–772CrossRef

Kennard BD, Silva SG, Tonev S et al. (2009) Remission and recovery in the treatment for adolescents with depression study (TADS): Acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry 48:186–195PubMedPubMedCentralCrossRef

Khoo AL, Zhou HJ, Teng M et al. (2015) Network meta-analysis and cost-effectiveness analysis of new generation antidepressants. CNS Drugs 29:695–712PubMedCrossRef

Kim Y, Myung SK, Jeon YJ et al. (2011) Effectiveness of pharmacologic therapy for smoking cessation in adolescents smokers: meta-analysis of randomized controlled trials. Am J Heal Ph 68:219–226

King BH, Hollander E, Sikich L et al. (2009) Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. STAART Psychopharma-cology Network. Arch Gen Psychiatry 66:583–590PubMedPubMedCentralCrossRef

Kong W, Deng H, Wan J et al. (2020) Comparative remission rates and tolerability of drugs for generalised anxiety disorder: a systematic review and network meta-analysis of double-blind randomized controlled trials. Front Pharmacol 11:580858PubMedPubMedCentralCrossRef

Kotler LA, Devlin MJ, Walsh BT (2002) Eating disorders and related disturbances. In: Kutcher S (Hrsg) Practical child and adolescent psychopharmacology. Cambridge University Press, Cambridge, S 410–430CrossRef

Krause M, Gutsmiedl K, Bighelli I et al. (2019) Efficacy and tolerability of pharmacological and nonpharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis. Eur Neuropsychopharmacol 29:1003–1022PubMedCrossRef

Kweon K, Kim HW (2019) Effectiveness and safety of bupropion in children and adolescents with depressive disorders: A retrospective chart review. Clin Psychopharmacol Neurosci 17:537–541PubMedPubMedCentralCrossRef

Lagerberg T, Fazel S, Sjölander A et al. (2021) Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study. Neuropsychopharmacology 47:817–823. https://doi.org/10.1038/s41386-021-01179-zCrossRefPubMedPubMedCentral

Lally N, Nugent AC, Luckenbaugh DA et al. (2014) Anti-anhedonic effect of ketamine and ist neural correlates in treatment-resistant bipolar depression. Transl Psychiatry 4:e469PubMedPubMedCentralCrossRef

Lee MS, Yang JW, Ko YH et al. (2008) Effects of methylphenidate and bupropion on DHEA-S and cortisol plasma levels in attention-deficit hyperactivity disorder. Child Psychiat Hum D 39:201–209CrossRef

Lesch K-P (2002) Exkurs: Wirkmechanismus antidepressiver Behandlung: Genexpression und synaptische Plastizität. In: Riederer P, Laux G, Pöldinger W (Hrsg) Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer, 2. Aufl. Neuro-Psychopharmaka. Ein Therapie-Handbuch, Bd. 3. Springer, Wien, S 31–55

Lotufo-Neto F, Trivedi M, Thase M (1999) Meta-Analysis of the reversible inhibitors of monoamine oxidase type A inhibitors moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 20:226–247PubMedCrossRef

Lundmark E, Nevéus T (2009) Reboxetine in therapy-resistant enuresis: a retrospective evaluation. Scand J Urol Nephrol 43:365–368PubMedCrossRef

Lundmark E, Stenberg A, Hägglöf B, Nevéus T (2016) Rebo-xetine in therapy-resistant enuresis: a randomized placebo-controlled study. J Pediatr Urol 12:397CrossRef

Macedo D, Filho AJM, Soares de Sousa CN et al. (2017) Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness. J Affect Disord 208:22–32PubMedCrossRef

Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL (1997) Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 33:149–154PubMed

March J, Silva S, Petrycki S et al. (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292:807–820 (Treatment for Adolescents with Depression Study (TADS) Team)PubMedCrossRef

March JS, Silva S, Petrycki S et al. (2007a) The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiat 64:1132–1143PubMedCrossRef

March JS, Entusah AR, Rynn M, Albano AM, Tourian KA (2007b) A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiat 62:1149–1154PubMedCrossRef

Marvanova M, Gramith K (2018) Role of antidepressants in the treatment of adults with anorexia nervosa. Ment Health Clin 26:127–137CrossRef

Masi G, Mucci M, Millepiedi S (2001) Separation anxiety disorder in children and adolescents: epidemiology, diagnosis and management. CNS Drugs 15:93–104PubMedCrossRef

McGrath PJ, Rabkin JG, Stewart JW et al. (1985) Placebo-controlled study of mianserin in depressed outpatients. Neuropsychobiology 14:128–132PubMedCrossRef

Meißner T (2021) Esketamin Nasenspray in der depressiven Akutphase. Sonderbericht in Psychopharmakotherapie: 28, PPT Report Nr. 15

Methling M, Krumbiegel F, Hartwig S, Parr MK, Tsokos M (2019) Toxicological fin-dings in suicides – frequency of antidepressant and antipsychotic substances. Forensic Sci Med Pathol 15:23–30PubMedCrossRef

Meyer JH, Wilson AA, Sagrati S et al. (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses. An [11C]DASB positron emission tomography study. Am J Psychiatry 161:826–835PubMedCrossRef

Mitchell JE, Raymond N, Specke S (1993) A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa. Int J Eat Disord 14:229–247PubMedCrossRef

Monuteaux MC, Spencer TJ, Faraone SV, Wilson AM, Biederman J (2007) A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder. J Clin Psychiatry 68:1094–1101PubMedCrossRef

Moreira R (2011) The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clin Drug Invest 31(Suppl 1):5–17CrossRef

Moreno C, Arango C, Parellada M, Shaffer D, Bird H (2007) Antidepressants in child and adolescent depression: where are the bugs? Acta Psychiatr Scand 115:184–195PubMedCrossRef

Mosholder AD, Willy M (2006) Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis. J Child Adol Psychop 16:25–32CrossRef

Mozes T, Meiri G, Ben-Amity G, Sabbagh M, Weizman A (2005) Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial. J Child Adol Psychoph 15:259–269CrossRef

Mrakotsky C, Masek B, Biederman J et al. (2008) Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia. J Anxiety Disord 22:88–97PubMedCrossRef

Müller N, Schennach R, Riedel M, Möller H-J (2008) Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Rev Neurother 8:527–536PubMedCrossRef

Mueller SC, Majcher-Peszynska J, Mundkowski RG et al. (2009) No clinically relevant CYP3A induction after St. John’s wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol 65:81–87PubMedCrossRef

Müller WE, Möller HJ (2002a) Einteilung nach klinisch-therapeutischen Wirkprofilen, sedierende vs. eher nicht sedierende Antidepressiva. In: Riederer P, Laux G, Pöldinger W (Hrsg) Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer, 2. Aufl. Neuro-/Psychopharmaka. Ein Therapie-Handbuch, Bd. 3. Springer, Wien, S 94–96

Müller WE, Möller HJ (2002b) Antidepressiva. Biochemisch-pharmakologische Wirkungsmechanismen. In: Riederer P, Laux G, Pöldinger W (Hrsg) Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer, 2. Aufl. Neuro-/Psychopharmaka. Ein Therapie-Handbuch, Bd. 3. Springer, Wien, S 84–87

Murray ML, Wong IC, Thompson M (2005) Do selective serotonin reuptake inhibitors cause suicide? Antidepressant prescribing to children and adolescents by GPs has fallen since CSM advice. BMJ 330:1151PubMedPubMedCentralCrossRef

Namerow L, Thomas P, Bostic JQ, Prince J, Monuteaux MC (2003) Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 24:104–108PubMedCrossRef

Nasir M, Li F, Courley S, Olten B, Bloch MH (2021) Meta-analysis: Pediatric placebo response in depression trials does not replicate in anxiety and obsessive-compulsive disorder trials. J Child Adolesc Psychopharmacol 31:670–684

National Institute for Health and Care Excellence (2013) NICE Clinical guideline [CG159] Social anxiety disorder: recognition, assessment and treatment. Published 22 May 2013

National Institute for Health and Care Excellence, NICE guideline [NG134] Depression in children and young people: identification and management. Published: 25 June 2019

Nationale VersorgungsLeitlinie Unipolare Depression (2022) Version 3.1, AWMF-Register-Nr. nvl-005

Nevéus T (2006) Reboxetine in therapy-resistant enuresis: results and pathogenetic implications. Scand J Urol Nephrol 40:31–34PubMedCrossRef

Niederhofer H (2012) Agomelatine treatment with adolescents with ADHD. J Atten Disord 16:530–532PubMedCrossRef

Niederhofer H, Huber M (2004) Bupropion may support psychosocial treatment of nicotine-dependent adolescents: preliminary results. Pharmacotherapy 24:1524–1528PubMedCrossRef

Normann C, Frase S, Haug V et al. (2018) Antidepressants rescue stress-induced disruption of synaptic plasticity via serotonin transporter-independent inhibition of L-type calcium channels. Biol Psychiatry 84:55–64PubMedCrossRef

Northoff G (2013) Gene, brains, and environment-genetic neuroimaging of depression. Curr Opin Neurobiol 23:133–142PubMedCrossRef

O’Leary LA, Mechawar N (2021) Implication of cerebral astrocytes in major depression: a review of fine neuroanatomical evidence in humans. Glia 69:2077–2209PubMedCrossRef

Otasowie J, Castells X, Ehimare UP, Smith CH (2014) Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006997.pub2CrossRefPubMed

Papanikolaou K, Richardson C, Pehlivanidis A, Papadopoulou-Daifoti Z (2006) Efficacy of antidepressants in child and adolescent depression: a meta-analytic study. J Neural Transm 113:399-415PubMedCrossRef

Pathak S, Kratochvil CJ, Rogers GM et al. (2005) Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study. Curr Psychiat Rep 7:429–434CrossRef

Pössel P, Hautzinger M (2006) Effects of pharmaco- and psychotherapeutic interventions in depression among children and adolescents. Z Kinder Jugend Psych 34:243–255CrossRef

Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ (2001) A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adol Psychop 11:267–277CrossRef

Powers PS, Bruty H (2009) Pharmacotherapy for eating disorders and obesity. Child Adolesc Psychiatr Clin N Am 18:175–187PubMedCrossRef

Prakash A, Lobo E, Kratochvil CJ et al. (2012) An open-label safety and pharmacokinetic study of duloxetine in pediatric patients with major depression. J Child Adol Psychop 22:48–55CrossRef

Prince JB, Wilens TE, Biederman J et al. (2000) A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adol Psychop 10:193–204CrossRef

Procyshyn RM, Bezchlibnyk-Butler KZ, Jeffries JJ (Hrsg) (2021) Clinical handbook of psychotropic drugs, 24. Aufl. Hogrefe

Quera-Salva MA, Lemoine P, Guilleminault C (2010) Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol 25:222–229PubMedCrossRef

Quintero J, López-Muñoz F, Alamo C, Loro M, García-Campos N (2011) Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study. Atten Defic Hyperact Disord 2:107–113CrossRef

Ratner S, Laor N, Bronstein Y, Weizman A, Toren P (2005) Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Psy 44:428–433CrossRef

Riahi F, Tashakori A, Izadi-Mazidi S, Salehi-Veysi M (2013) Effectiveness of reboxetine in treatment of outpatient children and adolescents with attention defi-cit-hyperactivity disorder with comorbid anxiety disorders. Iran J Psychiatry 8:195–200PubMedPubMedCentral

Robb AS, Cueva JE, Sporn J, Yang RY, Vanderburg DG (2010) Sertraline treatment of children and adolescents with posttraumatic stress disorder: A double-blind, placebo-controlled trial. J Child Adol Psychop 20:463–471CrossRef

Romano SJ, Halmi KA, Neena PS, Koke SC, Lee JS (2002) A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry 159:96–102PubMedCrossRef

Roth G, Strüber G (2014) Wie das Gehirn die Seele macht. Klett-Cotta, Stuttgart

Rynn MA, Siqueland L, Rickels K (2001) Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiat 158:2008–2014PubMedCrossRef

Rynn M, Wagner KD, Donnelly C et al. (2006) Long-term sertraline treatment of children and adolescents with major depressive disorder. J Child Adol Psychop 16:103–116CrossRef

Rynn MA, Riddle MA, Yeung PP, Kunz NR (2007) Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiat 164:290–300PubMedCrossRef

Salardini E, Zeinoddini A, Kohi A et al. (2016) Agomelatine as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double-blind, randomized clinical trial. J Child Adolesc Psychopharmacol 26:513–519PubMedCrossRef

Sarris J (2013) St. John’s wort for the treatment of psychiatric disorders. Psychiat Clin N Am 36:65–72CrossRef

Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A (2011) Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. Eur Neuropsychopharm 21:841–860CrossRef

Schlamp D (1999) Remergil in der Kinder- und Jugendpsychiatrie. Psychiatr Dialog 3:8–9

Schneeweiss S, Patrick AR, Solomon DH et al. (2010) Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics 125:876–888PubMedCrossRef

Segool NK, Carlson JS (2008) Efficacy of cognitive-behavioral and pharmacological treatments for children with social anxiety. Depress Anxiety 25:620–631PubMedCrossRef

Selph S, Patnode C, Bailey SR et al. (2020) Primary care-relevant interventions for tobacco and nicotine use prevention and cessation in children and adolescents: updated evidence report and systematic review for the US preventive services task force. JAMA 323:1599–1608PubMedCrossRef

Shah R, Uren Z, Baker A, Majeed A (2001) Deaths from antidepressants in England and Wales 1993–1997: analysis of a new national database. Psychol Med 31:1203–1210PubMedCrossRef

Shah AA, Khawaja IS, Aftab A (2015) Are psychotropic drugs safe to use during pregnancy? Psychiatr Ann 45:71–76CrossRef

Simeon J, Nixon MK, Milin R, Jovanovic R, Walker S (2005) Open-label pilot study of St. John’s wort in adolescent depression. J Child Adol Psychop 15:293–301CrossRef

Singh T, Prakash A, Rais T, Kumari N (2009) Decreased use of antidepressants in youth after US food and drug administration black box warning. Psychiatry (Edgmont) 6:30–34PubMed

Skapinakis P, Caldwell DM, Hollingworth W et al. (2016) Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry 3:730–739PubMedPubMedCentralCrossRef

Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Brit J Psychiat 180:396–404PubMedCrossRef

SOFIA-Study (2012) Neuropharm: clinicaltrails.gov. Study of fluoxetine in autism (SO-FIA). https://clinicaltrials.gov/ct2/show/NCT00515320

Sonmez AI, Almorsy A, Ramsey LB, Strawn JR, Croarkin PE (2020) Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations. Depress Anxiety 37:747–759PubMedPubMedCentralCrossRef

Spencer T, Biederman J, Coffey B et al. (2002) A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiat 59:649–656PubMedCrossRef

Spindelegger CJ, Papageorgiou K, Grohmann R et al. (2015) Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010. Int J Neuropsychopharmacol 18:4. https://doi.org/10.1093/ijnp/pyu080CrossRef

Stein DJ, Khoo JP, Ahokas A et al. (2018) 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder. Eur Neuropsychopharmacol 28:970–997PubMedCrossRef

Steingard RJ, Zimnitzky B, DeMaso DR, Bauman ML, Bucci JP (1997) Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adol Psychop 7:9–15CrossRef

Stoddard FJ Jr, Luthra R, Sorrentino EA et al. (2011) A randomized controlled trial of sertraline to prevent posttraumatic stress disorder in burned children. J Child Adol Psychop 21:469–477CrossRef

Storosum JG, Elferink AJ, van Zwieten BJ et al. (2001) Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharm 11:173–180CrossRef

Strawn JR, Prakash A, Zhang Q et al. (2015) A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry 54: 283–93PubMedCrossRef

Szegedi A, Wetzel H, Angersbach D, Philipp M, Benkert O (1997) Response to treatment in minor and major depression: results of a double-blind comparative study with paroxetine and maprotiline. J Affect Disord 45:167–178PubMedCrossRef

Tao R, Emslie GJ, Mayes TL, Nakonezny PA, Kennard BD (2010) Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder. J Child Adol Psychop 20:423–430CrossRef

Tehrani-Doost M, Moallemi S, Shahrivar Z (2008) An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adol Psychop 18:179–184CrossRef

Thomé-Souza MS, Kuczynski E, Valente KD (2007) Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy Behav 10:417–425PubMedCrossRef

Toren P, Ratner S, Laor N, Lerer-Amisar D, Weizman A (2005) A possible antienuretic effect of reboxetine in children and adolescents with attention deficit/hyperactivity disorder: case series. Neuropsychobiology 51:239–242PubMedCrossRef

Toren P, Ratner S, Weizman A et al. (2007) Reboxetine maintenance treatment in children with attention-deficit/hyperactivity disorder: a long-term follow-up study. J Child Adol Psychop 17:803–812CrossRef

Trott GE, Friese HJ, Menzel M, Nissen G (1992) Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology 106(Suppl 1):134–146CrossRef

Ueda N, Yoshimura R, Umene-Nakano W et al. (2009) Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. World J Biol Psychia 10:832–835CrossRef

Ulrich S, Hiemke C, Laux G et al. (2007) Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: A comparison with the medico-scientific evidence. Pharmacopsychiatry 40:121–127 (TDM group of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP))PubMedCrossRef

Usala T, Clavenna A, Zuddas A, Bonati M (2008) Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur Neuropsychopharm 18:62–73CrossRef

Ushakova VM, Morozova AY, Reznik AM, Kostyuk GP, Chekhonin VP (2020) Molecular biological aspects of depressive disorders. Mol Biol 54:639–660CrossRef

Van den Anker JN (2010) Developmental pharmacology. Dev Disabil Res Rev 16:233–238PubMedCrossRef

Varigonda AL, Jakubovski E, Bloch MH (2016) Systematic review and meta-analysis: Early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 55:851–859PubMedPubMedCentralCrossRef

Vaughn SE, Strawn JR, Poweleit EA, Sarangdhar M, Ramsey LB (2021) The impact of marijuana on antidepressant treatment in adolescents: clinical and pharmacological consideration. J Pers Med 11:615. https://doi.org/10.3390/jpm11070615CrossRefPubMedPubMedCentral

Versiani M, Amrein R, Stabl M (1997) Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. Int Clin Psychopharm 12:183–193CrossRef

Volkers AC, Heerdink ER, van Dijk L (2007) Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf 16:1054-1062PubMedCrossRef

Volz H-P (2012) Tianeptin – ein Antidepressivum mit „untypischem“ Wirkungsmechanismus. Psychopharmakotherapie 19:253–259

Von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hultén A (2006) A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharm 26:311–315CrossRef

Wagner KD, Ambrosini P, Rynn M (2003) Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 290:1033–1041 (Sertraline Pediatric Depression Study Group)PubMedCrossRef

Wagner KD, Robb AS, Findling RL et al. (2004a) A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 161:1079–1083PubMedCrossRef

Wagner KD, Berard R, Stein MB et al. (2004b) A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiat 61:1153–1162PubMedCrossRef

Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K (2006) A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 45:280–288PubMedCrossRef

Walkup JT, Labellarte MJ, Riddle MA et al. (2001) Fluvoxamine for the treatment of anxiety disorders in children and adolescent. N Engl J Med 344:1279–1285 (for the Research Unit on Pediatric Psychopharmacology Anxiety Study Group)CrossRef

Walsh BT, Develin MJ (1992) The pharmacologic treatment of eating disorders. Psychiatr Clin North Am 15:149–160PubMedCrossRef

Walsh BT, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression: Variable, substantial, and growing. JAMA 287:1840–1847PubMedCrossRef

Walsh BT, Kaplan AS, Attia E et al. (2006) Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA 295:2605–2612 (Erratum in: JAMA (2007) 298: 2008, JAMA (2006) 296: 934)PubMedCrossRef

Wang K, Sun A, Li L, Tu M, Jiang H (2014) Involvement of organic cation transporter 2 inhibition in potential mechanisms of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 53:90–98PubMedCrossRef

Weber W, Vander SA, McCarty RL et al. (2008) Hypericum perforatum (St John’s wort) for attention-deficit/hyperactivity disorder in children and adol-escents: a randomized controlled trial. JAMA 299:2633–2641PubMedPubMedCentralCrossRef

Weller TE, Weller RA, Davis GP (2000) Use of venlafaxine in children and adolescents: a review of current literature. Depress Anxiety 1(Suppl 12):85–99CrossRef

Werneke U, Horn O, Taylor DM (2004) How effective is St John’s wort? The evidence revisited. J Clin Psychiat 65:611–617CrossRef

White MA, Grilo CM (2013) Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiat 74:400–406CrossRef

Wilcox CS, Cohn JB, Katz BB et al. (1994) A double-blind, placebo-controlled study comparing mianserin and amitriptyline in moderately depressed outpatients. Int Clin Psychopharm 9:271–279CrossRef

Williams K, Brignell A, Randall M, Silove N, Hazell P (2013) Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004677.pub2CrossRefPubMedPubMedCentral

Witkin JM, Knutson DE, Rodriguez GJ, Shi S (2018) Rapid-Acting antidepressants. Curr Pharm Design 24:2256–2563CrossRef

Woggon B (1993) The role of moclobemide in endogenous depression: a survey of recent data. Int Clin Psychopharm 7:137–139CrossRef

Wood JG, Crager JL, Delap CM, Heiskell KD (2007) Beyond methylphenidate: nonstimulant medications for youth with ADHD. J Attent Disord 11:341–350CrossRef

Yang LP, Scott LJ (2010) Escitalopram: in the treatment of major depressive disorder in adolescent patients. CNS Drugs 24:621–623PubMedCrossRef

Zhou X, Teng T, Zhang Y et al. (2020) Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry 7:581–601PubMedPubMedCentralCrossRef

Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (2013) S3-Leitlinie Behandlung von depressiven Störungen bei Kindern und Jugendlichen (AWMF-Registernummer 028–043)

Nationale VersorgungsLeitlinie Unipolare Depression (2022) Version 3.1, AWMF-Register-Nummer nvl-005

Titel: Antidepressiva
verfasst von: Priv.-Doz. Dr. med. Regina Taurines
Prof. Dr. rer. nat. Manfred Gerlach
Verlag: Springer Berlin Heidelberg
Buch: Neuro-/Psychopharmaka im Kindes- und Jugendalter
Print ISBN: 978-3-662-65266-4

Electronic ISBN: 978-3-662-65267-1

Copyright-Jahr: 2023
DOI: https://doi.org/10.1007/978-3-662-65267-1_5

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).